Adaptation to excess acetylcholine by downregulation of adrenoceptors and muscarinic receptors in lungs of acetylcholinesterase knockout mice
Language English Country Germany Media print-electronic
Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.
Grant support
P30CA36727
NCI NIH HHS - United States
- MeSH
- Acetylcholine metabolism MeSH
- Acetylcholinesterase genetics MeSH
- Receptors, Adrenergic biosynthesis MeSH
- Cyclic AMP biosynthesis MeSH
- Down-Regulation MeSH
- Phosphatidylinositols metabolism MeSH
- Type C Phospholipases metabolism MeSH
- Immunoassay MeSH
- Mice, Knockout MeSH
- Mice MeSH
- Lung metabolism MeSH
- GTP-Binding Proteins metabolism MeSH
- Radioligand Assay MeSH
- Receptors, Muscarinic biosynthesis MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Research Support, N.I.H., Extramural MeSH
- Research Support, U.S. Gov't, Non-P.H.S. MeSH
- Names of Substances
- Acetylcholine MeSH
- Acetylcholinesterase MeSH
- Receptors, Adrenergic MeSH
- Cyclic AMP MeSH
- Phosphatidylinositols MeSH
- Type C Phospholipases MeSH
- GTP-Binding Proteins MeSH
- Receptors, Muscarinic MeSH
The acetylcholinesterase knockout mouse has elevated acetylcholine levels due to the complete absence of acetylcholinesterase. Our goal was to determine the adaptive changes in lung receptors that allow these animals to tolerate excess neurotransmitter. The hypothesis was tested that not only muscarinic receptors but also alpha(1)-adrenoceptors and beta-adrenoceptors are downregulated, thus maintaining a proper balance of receptors and accounting for lung function in these animals. The quantity of alpha(1A), alpha(1B), alpha(1D), beta(1), and beta(2)-adrenoceptors and muscarinic receptors was determined by binding of radioligands. G-protein coupling was assessed using pseudo-competition with agonists. Phospholipase C activity was measured by an enzymatic assay. Cyclic AMP (cAMP) content was measured by immunoassay. Muscarinic receptors were decreased to 50%, alpha(1)-adrenoceptors to 23%, and beta-adrenoceptors to about 50% of control. Changes were subtype specific, as alpha(1A), alpha(1B), and beta(2)-adrenoceptors, but not alpha(1D)-adrenoceptor, were decreased. In contrast, receptor signaling into the cell as measured by coupling to G proteins, cAMP content, and PI-phospholipase C activity was the same as in control. This shows that the nearly normal lung function of these animals was explained by maintenance of a correct balance of adrenoceptors and muscarinic receptors. In conclusion, knockout mice have adapted to high concentrations of acetylcholine by downregulating receptors that bind acetylcholine, as well as by downregulating receptors that oppose the action of muscarinic receptors. Tolerance to excess acetylcholine is achieved by reducing the levels of muscarinic receptors and adrenoceptors.
See more in PubMed
Pharmacol Ther. 1990;48(3):295-322 PubMed
Ann Neurol. 2003 Jun;53(6):788-96 PubMed
Trends Neurosci. 2006 Mar;29(3):140-7 PubMed
Am J Physiol. 1997 Sep;273(3 Pt 1):G586-601 PubMed
J Biol Chem. 2004 Nov 5;279(45):46882-9 PubMed
Pharmacol Ther. 2006 Jul;111(1):260-71 PubMed
J Mol Neurosci. 2006;30(1-2):69-70 PubMed
Mol Cell Neurosci. 2003 May;23(1):121-33 PubMed
J Pharmacol Exp Ther. 2000 Jun;293(3):896-902 PubMed
Biochem Pharmacol. 1998 May 1;55(9):1419-26 PubMed
Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 3):S154-60 PubMed
Mol Pharmacol. 2003 Dec;64(6):1309-16 PubMed
Physiol Rev. 1999 Oct;79(4):1373-430 PubMed
Anal Biochem. 1977 Dec;83(2):346-56 PubMed
Muscle Nerve. 2004 Sep;30(3):317-27 PubMed
Life Sci. 1996 May 24;58(26):2423-30 PubMed
Eur Respir J. 2000 Jun;15(6):1120-7 PubMed
Eur J Neurosci. 2003 Sep;18(6):1419-27 PubMed
Life Sci. 2006 Jun 6;79(2):112-20 PubMed
J Comp Neurol. 2003 Jun 9;462(3):302-14 PubMed
J Neurochem. 1999 Aug;73(2):780-90 PubMed
Brain Res Dev Brain Res. 2002 Jul 30;137(1):43-54 PubMed
Toxicol Appl Pharmacol. 1986 Jul;84(3):541-50 PubMed
Crit Care. 2002 Aug;6(4):335-41 PubMed
Neuroscience. 2004;125(4):1009-17 PubMed
J Pharmacol Exp Ther. 2001 Nov;299(2):528-35 PubMed
Respir Physiol Neurobiol. 2004 Jun 25;140(3):231-41 PubMed
Life Sci. 2006 Dec 3;80(1):17-23 PubMed
Pharmacol Biochem Behav. 2003 Mar;74(4):977-86 PubMed
Naunyn Schmiedebergs Arch Pharmacol. 2006 Nov;374(2):99-105 PubMed
Life Sci. 1997;60(13-14):1061-8 PubMed
Naunyn Schmiedebergs Arch Pharmacol. 2003 Nov;368(5):366-76 PubMed
Toxicology. 1982;25(2-3):79-97 PubMed
J Neurochem. 2007 Mar;100(5):1421-9 PubMed
Biochem Pharmacol. 2003 Sep 15;66(6):1067-81 PubMed
Adv Exp Med Biol. 2004;551:165-70 PubMed
Developmental adaptation of central nervous system to extremely high acetylcholine levels